{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:10:00Z","timestamp":1792843800496,"version":"4.5.0"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2019\/35\/B\/NZ5\/02824"],"award-info":[{"award-number":["2019\/35\/B\/NZ5\/02824"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Multiple myeloma is an incurable cancer that originates from antibody-producing plasma cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin-like proteins. The high rate of synthesis makes myeloma cells dependent on protein processing mechanisms related to the proteasome. This dependence made proteasome inhibitors such as bortezomib and carfilzomib one of the most important classes of drugs used in multiple myeloma treatment. Inhibition of the proteasome is associated with alteration of a number of important biological processes leading, in consequence, to inhibition of angiogenesis. The effect of drugs in this group and the degree of patient response to the treatment used is itself an extremely complex process that depends on many factors. At cellular level the change in sensitivity to proteasome inhibitors may be related to differences in the expression level of proteasome subunits, the degree of proteasome loading, metabolic adaptation, transcriptional or epigenetic factors. These are just some of the possibilities that may influence differences in response to proteasome inhibitors. This review describes the main cellular factors that determine the degree of response to proteasome inhibitor drugs, as well as information on the key role of the proteasome and the performance characteristics of the inhibitors that are the mainstay of multiple myeloma treatment.<\/jats:p>","DOI":"10.3389\/fphar.2024.1351565","type":"journal-article","created":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T23:52:50Z","timestamp":1709509970000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells"],"prefix":"10.3389","volume":"15","author":[{"given":"Marta","family":"Pelon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patryk","family":"Krzeminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Tracz-Gaszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Misiewicz-Krzeminska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.3892\/ol.2015.3545","article-title":"Bortezomib attenuates HIF-1- but not HIF-2-Mediated transcriptional activation","volume":"10","author":"Abd-Aziz","year":"2015","journal-title":"Oncol. Lett."},{"key":"B2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s1359-6446(03)02647-3","article-title":"Potential for proteasome inhibition in the treatment of cancer","volume":"8","author":"Adams","year":"2003","journal-title":"Drug Discov. Today"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1038\/onc.2009.264","article-title":"Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)","volume":"28","author":"Arlt","year":"2009","journal-title":"Oncogene"},{"key":"B4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/sj.leu.2404466","article-title":"Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma","volume":"21","author":"Arnulf","year":"2007","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.leukres.2011.09.011","article-title":"Bortezomib resistance in a myeloma cell line is associated to PSM\u03b25 overexpression and polyploidy","volume":"36","author":"Balsas","year":"2012","journal-title":"Leukemia Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40164-023-00434-x","article-title":"Lysin (K)-Specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma","volume":"12","author":"Bandini","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and function of the 26S proteasome","volume":"87","author":"Bard","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1158\/0008-5472.CAN-05-2321","article-title":"Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis","volume":"66","author":"Bazzaro","year":"2006","journal-title":"Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood-2018-05-850826","article-title":"IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies","volume":"133","author":"Bergaggio","year":"2019","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0076-6879(05)99039-3","article-title":"Development and characterization of proteasome inhibitors","volume":"399","author":"Bo Kim","year":"2005","journal-title":"Methods Enzym."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3389\/fonc.2019.01530","article-title":"Spliced XBP1 levels determine sensitivity of multiple myeloma cells to proteasome inhibitor bortezomib independent of the unfolded protein response mediator GRP78","volume":"9","author":"Borjan","year":"2019","journal-title":"Front. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3109\/10428194.2013.806799","article-title":"Bortezomib inhibits proteasomal degradation of I\u03baB\u03b1 and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma","volume":"55","author":"Bu","year":"2014","journal-title":"Leukemia Lymphoma"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1016\/j.jmb.2017.05.027","article-title":"Proteasome structure and assembly","volume":"429","author":"Budenholzer","year":"2017","journal-title":"J. Mol. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/cncr.23224","article-title":"Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits","volume":"112","author":"Busse","year":"2008","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.3892\/mmr.2016.5658","article-title":"Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells","volume":"14","author":"Cao","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","article-title":"Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells","volume":"108","author":"Catley","year":"2006","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin. Cancer Res. An Official J. Am. Assoc. Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"B20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12272-021-01316-8","article-title":"The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance","volume":"44","author":"Choi","year":"2021","journal-title":"Archives Pharmacal Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"11840","DOI":"10.1074\/jbc.M413007200","article-title":"Overexpression of proteasome Beta5 assembled subunit increases the amount of proteasome and confers ameliorated response to oxidative stress and higher survival rates","volume":"280","author":"Chondrogianni","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/cancers11050731","article-title":"STAT3: a promising therapeutic target in multiple myeloma","volume":"11","author":"Chong","year":"2019","journal-title":"Cancers"},{"key":"B24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.12688\/f1000research.6835.2","article-title":"Intracellular dynamics of the ubiquitin-proteasome-system","volume":"4","author":"Chowdhury","year":"2015","journal-title":"F1000Research"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1038\/nrm1552","article-title":"Proteolysis: from the lysosome to ubiquitin and the proteasome","volume-title":"Nature reviews molecular cell biology","author":"Ciechanover","year":"2005"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2009.06.065","article-title":"Tracing the history of the ubiquitin proteolytic system: the pioneering article","volume-title":"Biochemical and biophysical research communications","author":"Ciechanover","year":"2009"},{"key":"B27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The logic of the 26S proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1385\/1-59259-895-1:305","article-title":"Aggresome Formation","volume":"301","author":"Corboy","year":"2005","journal-title":"Methods Mol. Biol. Clift. N.J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12079-011-0121-7","article-title":"Proteasome inhibitors in cancer therapy","volume":"5","author":"Crawford","year":"2011","journal-title":"J. Cell Commun. Signal."},{"key":"B30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2165\/00003495-200969070-00006","article-title":"Bortezomib: a review of its use in patients with multiple myeloma","volume":"69","author":"Curran","year":"2009","journal-title":"Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1038\/bcj.2014.29","article-title":"The role of epigenetics in the biology of multiple myeloma","volume":"4","author":"Dimopoulos","year":"2014","journal-title":"Blood Cancer J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1517\/13543776.2015.1056737","article-title":"Deubiquitinases (DUBs) and DUB inhibitors: a patent review","volume":"25","author":"Farshi","year":"2015","journal-title":"Expert Opin. Ther. Pat."},{"key":"B34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (velcadetrade mark) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"B35","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/gb-2009-10-3-r29","article-title":"TFCat: the curated catalog of mouse and human transcription factors","volume":"10","author":"Fulton","year":"2009","journal-title":"Genome Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"B37","doi-asserted-by":"publisher","first-page":"848341","DOI":"10.3389\/fonc.2022.848341","article-title":"Circular RNAs and their role in exosomes","volume":"12","author":"Han","year":"2022","journal-title":"Front. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-KappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41419-022-04629-8","article-title":"NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma","volume":"13","author":"Huang","year":"2022","journal-title":"Cell Death Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.4161\/cbt.5.9.3001","article-title":"Reversal of P53 epigenetic silencing in multiple myeloma permits apoptosis by a P53 activator","volume":"5","author":"Hurt","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"15448","DOI":"10.3390\/ijms232415448","article-title":"Molecular features of the mesenchymal and osteoblastic cells in multiple myeloma","volume":"23","author":"Iannozzi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12013-013-9631-7","article-title":"Could dysregulation of UPS Be a common underlying mechanism for cancer and neurodegeneration? Lessons from UCHL1","volume":"67","author":"Jara","year":"2013","journal-title":"Cell Biochem. Biophysics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"740796","DOI":"10.3389\/fonc.2021.740796","article-title":"Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma","volume":"11","author":"Jayaweera","year":"2021","journal-title":"Front. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.5045\/br.2017.52.4.293","article-title":"STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma","volume":"52","author":"Jung","year":"2017","journal-title":"Blood Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and drug administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res. An Official J. Am. Assoc. Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"8171","DOI":"10.1074\/jbc.M109.031575","article-title":"Nuclear erythroid factor 2-mediated proteasome activation delays senescence in human fibroblasts","volume":"285","author":"Kapeta","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12885-015-1008-4","article-title":"Clinicopathological significance of nuclear factor (Erythroid-2)-Related factor 2 (Nrf2) expression in gastric cancer","volume":"15","author":"Kawasaki","year":"2015","journal-title":"BMC Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-1-4419-6676-6_6","article-title":"Mechanism, specificity and structure of the deubiquitinases","volume":"54","author":"Komander","year":"2010","journal-title":"Subcell. Biochem."},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1038\/nrm2731","article-title":"Breaking the chains: structure and function of the deubiquitinases","volume-title":"Nature reviews molecular cell biology","author":"Komander","year":"2009"},{"key":"B52","first-page":"3280","article-title":"Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response","volume":"12","author":"Kubicki","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1182\/blood.V116.21.4992.4992","article-title":"IDH1 and IDH2 mutations are not frequent in multiple myeloma","volume":"116","author":"Langer","year":"2010","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s11899-012-0141-2","article-title":"New proteasome inhibitors in myeloma","volume":"7","author":"Lawasut","year":"2012","journal-title":"Curr. Hematol. Malignancy Rep."},{"key":"B56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-Negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"key":"B57","doi-asserted-by":"publisher","first-page":"29854","DOI":"10.1074\/jbc.M115.664953","article-title":"The nuclear factor (Erythroid-Derived 2)-like 2 and proteasome maturation protein Axis mediate bortezomib resistance in multiple myeloma","volume":"290","author":"Li","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"21353","DOI":"10.18632\/oncotarget.7241","article-title":"Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature","volume":"7","author":"Lionetti","year":"2016","journal-title":"Oncotarget"},{"key":"B59","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.phrs.2016.01.029","article-title":"Oxidative stress and proteasome inhibitors in multiple myeloma","volume":"105","author":"Lipchick","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41419-018-0522-0","article-title":"O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance","volume":"9","author":"Liu","year":"2018","journal-title":"Cell Death Dis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/BF00581261","article-title":"Effect of triiodothyronine on (Na+ G K+)-Adenosine triphosphatase and (Na+ + Mg2+)-dependent phosphorylated intermediate in rat salivary glands","volume":"392","author":"Lo","year":"1981","journal-title":"Pflugers Archiv Eur. J. Physiology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"248","DOI":"10.4274\/tjh.galenos.2020.2020.0243","article-title":"Circulating exosomal CircMYC is associated with recurrence and bortezomib resistance in patients with multiple myeloma","volume":"37","author":"Luo","year":"2020","journal-title":"Turkish J. Haematol. Official J. Turkish Soc. Haematol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-14-3400","article-title":"Metabolic signature identifies novel targets for drug resistance in multiple myeloma","volume":"75","author":"Maiso","year":"2015","journal-title":"Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/1476-4598-9-176","article-title":"Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-KappaB activity in myeloma cells","volume":"9","author":"Markovina","year":"2010","journal-title":"Mol. Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.3390\/cancers15082199","article-title":"Euchromatic histone lysine methyltransferase 2 inhibition enhances carfilzomib sensitivity and overcomes drug resistance in multiple myeloma cell lines","volume":"15","author":"Mereu","year":"2023","journal-title":"Cancers"},{"key":"B67","doi-asserted-by":"publisher","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3892\/etm.2021.9628","article-title":"Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line kasumi-1","volume":"21","author":"Mpakou","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1126\/science.1141915","article-title":"Regulation of CD8 + T cell development by thymus-specific proteasomes","volume":"316","author":"Murata","year":"2007","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41590-018-0186-z","article-title":"The immunoproteasome and thymoproteasome: functions, evolution and human disease","volume":"19","author":"Murata","year":"2018","journal-title":"Nat. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.coi.2008.03.002","article-title":"Thymoproteasome: probable role in generating positively selecting peptides","volume":"20","author":"Murata","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF02705243","article-title":"The ubiquitin-proteasome system","volume":"31","author":"Nandi","year":"2006","journal-title":"J. Biosci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1038\/bcj.2015.98","article-title":"Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy","volume":"5","author":"Narita","year":"2015","journal-title":"Blood Cancer J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1182\/blood.v89.7.2500","article-title":"Frequent hypermethylation of P16 and P15 genes in multiple myeloma","volume":"89","author":"Ng","year":"1997","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"19488","DOI":"10.1073\/pnas.0708380104","article-title":"Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition","volume":"104","author":"Nikiforov","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B77","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: structure and function","volume":"44","author":"Nunes","year":"2017","journal-title":"Seminars Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit Beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/ERC-13-0234","article-title":"NRF2 immunolocalization in human breast cancer patients as a prognostic factor","volume":"21","author":"Onodera","year":"2014","journal-title":"Endocrine-Related Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.str.2009.06.011","article-title":"A tetrahedral transition state at the active sites of the 20S proteasome is coupled to opening of the alpha-ring channel","volume":"17","author":"Osmulski","year":"2009","journal-title":"Struct. Lond. Engl. 1993"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s10238-022-00850-z","article-title":"Emerging role of exosomes in hematological malignancies","volume":"23","author":"Pandian","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet. Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","article-title":"Bortezomib for the treatment of hematologic malignancies: 15 Years later","volume":"19","author":"Robak","year":"2019","journal-title":"Drugs R&D"},{"key":"B85","doi-asserted-by":"publisher","first-page":"936","DOI":"10.4161\/cbt.9.11.11882","article-title":"MDM2 antagonist Nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity","volume":"9","author":"Saha","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bbamcr.2013.08.012","article-title":"Regulation of proteasome activity in health and disease","volume":"1843","author":"Schmidt","year":"2014","journal-title":"Biochimica Biophysica Acta"},{"key":"B87","doi-asserted-by":"publisher","first-page":"21588","DOI":"10.1073\/pnas.2001323117","article-title":"Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis","volume":"117","author":"Sha","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B88","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1182\/blood-2007-11-120576","article-title":"Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1","volume":"111","author":"Shin","year":"2008","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03705-9","article-title":"Acute accumulation of PIM2 and NRF2 and recovery of \u03b25 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors","author":"Sogabe","year":"2024","journal-title":"Int. J. Hematol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1182\/blood.V128.22.3287.3287","article-title":"Dual activation of NRF2 in multiple myeloma and bone marrow mesenchymal stromal cells regulates chemotherapy resistance","volume":"128","author":"Sun","year":"2016","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"12958","DOI":"10.3390\/ijms222312958","article-title":"Merging the versatile functionalities of boronic acid with peptides","volume":"22","author":"Tan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cbin.11540","article-title":"Exosomal MRNAs and LncRNAs involved in multiple myeloma resistance to bortezomib","volume":"45","author":"Tang","year":"2021","journal-title":"Cell Biol. Int."},{"key":"B93","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/biom10050696","article-title":"Mitochondrial functions, energy metabolism and protein glycosylation are interconnected processes mediating resistance to bortezomib in multiple myeloma cells","volume":"10","author":"Tibullo","year":"2020","journal-title":"Biomolecules"},{"key":"B94","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1038\/s41467-022-34654-2","article-title":"The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma","volume":"13","author":"Vdovin","year":"2022","journal-title":"Nat. Commun."},{"key":"B95","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","article-title":"The impact of NF-\u03bab signaling on pathogenesis and current treatment strategies in multiple myeloma","volume":"34","author":"Vr\u00e1bel","year":"2019","journal-title":"Blood Rev."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.3389\/fpls.2018.01636","article-title":"Characterization of the ubiquitin C-terminal Hydrolase and ubiquitin-specific protease families in rice (oryza sativa)","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Plant Sci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e149526","DOI":"10.1172\/JCI149526","article-title":"Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation","volume":"132","author":"Wang","year":"2022","journal-title":"J. Clin. Investigation"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1182\/blood.2020005795","article-title":"MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e159839","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J. Clin. Investigation"},{"key":"B100","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/bjh.16503","article-title":"Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma","volume":"190","author":"Wu","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.2147\/OTT.S158206","article-title":"The role of HIF-1\u03b1 in chemo-\/radioresistant tumors","volume":"11","author":"Xia","year":"2018","journal-title":"OncoTargets Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e2219978120","DOI":"10.1073\/pnas.2219978120","article-title":"Proteasome inhibitor bortezomib stabilizes and activates P53 in hematopoietic stem\/progenitors and double-negative T cells in vivo","volume":"120","author":"Xue","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/cts.12836","article-title":"Early M-protein dynamics predicts progression-free survival in patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Yan","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s13238-017-0500-9","article-title":"Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-\u03bab signaling pathway","volume":"9","author":"Yang","year":"2018","journal-title":"Protein & Cell"},{"key":"B105","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s43556-021-00043-2","article-title":"E3 ubiquitin ligases: styles, structures and functions","volume":"2","author":"Yang","year":"2021","journal-title":"Mol. Biomed."},{"key":"B106","doi-asserted-by":"publisher","first-page":"113634","DOI":"10.1016\/j.yexcr.2023.113634","article-title":"The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6","volume":"429","author":"Yuan","year":"2023","journal-title":"Exp. Cell Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40170-017-0169-9","article-title":"Bortezomib resistance in multiple myeloma is associated with increased serine synthesis","volume":"5","author":"Zaal","year":"2017","journal-title":"Cancer & Metabolism"},{"key":"B108","doi-asserted-by":"publisher","first-page":"30876","DOI":"10.18632\/oncotarget.9021","article-title":"Potential role of exosome-associated MicroRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B109","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2016.03.026","article-title":"Tight junction protein 1 modulates proteasome capacity and proteasome inhibitor sensitivity in multiple myeloma via EGFR\/JAK1\/STAT3 signaling","volume":"29","author":"Zhang","year":"2016","journal-title":"Cancer Cell"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e0127334","DOI":"10.1371\/journal.pone.0127334","article-title":"Expression of GITR enhances multiple myeloma cell sensitivity to bortezomib","volume":"10","author":"Zhao","year":"2015","journal-title":"PloS One"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1080\/14656566.2017.1404575","article-title":"An overview of the role of carfilzomib in the treatment of multiple myeloma","volume":"18","author":"Ziogas","year":"2017","journal-title":"Expert Opin. Pharmacother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1351565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T23:52:57Z","timestamp":1709509977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1351565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":111,"alternative-id":["10.3389\/fphar.2024.1351565"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1351565","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"article-number":"1351565"}}